We are on a global mission to establish gene therapy as a new standard of care for highly prevalent ocular diseases.
Gene Therapy • Biotechnology • Rare Diseases • Ophthalmology • Retina
51 - 200
💰 $217M Post-IPO Equity on 2020-08
Yesterday
🔄 Hybrid – Bay Area
⏰ Full Time
🔴 Lead
🔧 QA Engineer (Quality Assurance)
🛂 H1B Visa Sponsor
Google Cloud Platform
September 2
🏡 Remote – Anywhere in California
🟠 Senior
⚙️ Operations
July 25
July 24
🏢 In-office - Bay Area
May 14
🚔 Compliance